We established an integrated platform of 53 patient-derived xenografts (PDXs) and matched patient-derived cancer cell models from 103 endometrial cancer specimens. Using high-throughput screening of 179 FDA-approved oncology drugs, we identified multiple therapeutic vulnerabilities that were not predicted by current standard-of-care approaches, providing a valuable resource for precision oncology and translational drug discovery.